Johnson & Johnson upgraded by Daiwa Securities with a new price target
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $203.00 | Neutral → Outperform | Daiwa Securities |
| 10/3/2025 | $212.00 | Equal Weight → Overweight | Wells Fargo |
| 9/23/2025 | $206.00 | Neutral → Buy | Guggenheim |
| 7/23/2025 | Hold → Buy | Erste Group | |
| 5/13/2025 | $153.00 | Outperform → Market Perform | Leerink Partners |
| 12/10/2024 | $166.00 | Neutral | BofA Securities |
| 11/15/2024 | $190.00 | Outperform | Wolfe Research |
| 7/23/2024 | $160.00 → $150.00 | Outperform → Neutral | Daiwa Securities |
3 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
144 - JOHNSON & JOHNSON (0000200406) (Subject)
Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00
Wells Fargo upgraded Johnson & Johnson from Equal Weight to Overweight and set a new price target of $212.00
Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J., Oct. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and plat
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results RARITAN, N.J., Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in com
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o
Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv
Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel
Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in
2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirm